NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.
September 29, 2020
Share
NanoCarrier Co., Ltd. (TSE:4571) signed an agreement to acquire remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka for ¥1.7 billion on July 15, 2020. Under the terms of transaction, NanoCarrier Co., Ltd. will issue 67.5 common shares for every one common stock of AccuRna; 138.3 shares for every 1 Class A Preferred Stock; 174 shares for every 1 Class B preferred stock and 198.3 for every 1 B2 class preferred stock. NanoCarrier will acquire 26.7% stake from Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd., 41.1% stake from Fast Track Initiative No. 2 Investment Business Limited Liability, 8.21% stake from SMBC Venture Capital Co., Ltd. and 9.23% from Kazunori Kataoka. The total shares issued by NanoCarrier as consideration will be 3.8 million new shares. For the year ended November 30, 2019, AccuRna reported sales of ¥5.7 million, total assets of ¥279.9 million, operating loss of ¥309.4 million and net assets of ¥203.7 million. The transaction is subject to approval from shareholders of NanoCarrier Co., Ltd. The transaction has been resolved by the Board of NanoCarrier Co., Ltd. The transaction is expected to be completed by September 1, 2020. Tajima CPA Office acted as a third-party institution for calculating the merger ratio.
NanoCarrier Co., Ltd. (TSE:4571) completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka on September 30, 2020.
Nano Mrna Co Ltd, formerly NanoCarrier Co Ltd, is mainly engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company develops businesses using the research and development of messenger ribonucleic acid (mRNA) medicine. The products under development are specialized in mRNA medicines. mRNA medicine is a medicine that prevents or treats diseases by administering artificially produced mRNA to the body and allowing the body to discover the protein encoded by the mRNA. Its pipeline includes RUNX1, the mRNA drug pipeline, non-mRNA drug pipeline, Comrex otological liquid 1.5%, NC-6100, TUG1, and others.
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.